| 摘要 |
<p>The use of a compound of formula (I) in which: R?1 and R2¿ are the same or different and each represents a hydrogen atom or a C¿1? - C5 alkyl group; R?3¿ represents a hydrogen atom, a C¿1? - C6 aliphatic acyl group, a (C5 - C7 cycloalkane) carbonyl group, an aromatic acyl group which is a benzoyl or naphthoyl group optionally with one or more nitro, amino, alkylamino, dialkylamino, alkoxy, halo, alkyl or hydroxy substituents, a heterocyclic acyl group having one or more oxygen, sulphur or nitrogen hetero atoms and with 4 to 7 ring atoms, an optionally halo-substituted phenylacetyl or phenylpropionyl group, a cinnamoyl group, a (C1 - C6 alkoxy) carbonyl group or a benzoyloxycarbonyl group; R?4 and R5¿ are the same or different and each represents a hydrogen atom, a C¿1? - C5 alkyl group or a C1 - C5 alkoxy group, or R?4 and R5¿ together represent a C¿1? - C4 alkylenedioxy group; n is 1, 2 or 3; W represents the -CH2, > CO or > CH-OR?6¿ group (in which R6 represents any one of the atoms or groups defined for R3 and may by the same as or different from R3); and Y and Z are the same or different and each represents an oxygen atom or an imino (=NH) group; or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the amelioration of inappropriate endothelial cell activation.</p> |
